REGISTERED NUMBER: 14582936 (England and Wales)

GOODWIN AND BROCKLEBANK MEDICAL LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2026

Page

Statement of Financial Position

1

FIXED ASSETS

10,720

482

CURRENT ASSETS

19,079

10,713

CREDITORS

Amounts falling due within one year

(7,214

)

(6,512

)

NET CURRENT ASSETS

11,865

4,201

TOTAL ASSETS LESS CURRENT LIABILITIES

22,585

4,683

CAPITAL AND RESERVES

22,585

4,683

NOTES TO THE FINANCIAL STATEMENTS

1.	STATUTORY INFORMATION

Goodwin and Brocklebank Medical Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

14582936

Registered office:

The Beeches Medical Practice

Beeches Road

Bayston Hill

Shrewsbury

SY3 0PF

2.	AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was NIL (2025 - NIL).

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 2 July 2026 and were signed on its behalf by:

Dr A Brocklebank - Director